We are increasingly confident about our next fiscal year as the changes at Archetype and Beyond work through alongside the full year impact of our more recently acquired businesses
Tim Dyson, Next Fifteen CEO
What it does
The group's aim is to build a group of specialised companies that can cover a wide range of sectors and geographies, allowing it maximum access to customers and international talent.
The latest addition to the stable is Health Unlimited, which provides communication services to companies involved in solving global health issues.
Previous clients include the International AIDS Society and the American Society of Clinical Oncology.
How is it doing?
Next Fifteen reported an adjusted pre-tax profit for the six months ended 31 July of £17.2mln, 14% higher than the prior year, while net revenues were up 11% at £118.7mln.
The interim dividend was also hiked 15.7% to 2.5p per share.
Organic revenue in the period fell 1.3%, which Next blamed on the restructuring of its Archetype business and the loss of Samsung and Just Eat at clients at its Beyond brand, although it continued to expect a return to “high single digit” organic growth in its next financial year.
- In early October, Next Fifteen announced it had acquired health consultancy and communications agency Health Unlimited in a US$27.7mln deal
- Tim Dyson, chief executive of Next Fifteen, said the purchase of Health Unlimited was a “major milestone” for the group which would add a specialist business to its portfolio and “greatly” expand its international footprint.
- In June, the group said it had appointed Helen Hunter, the chief data officer of FTSE 100 supermarket Sainsbury's, to the board as an independent non-executive director.
Interview - CEO Tim Dyson
Peel Hunt currently has Next Fifteen pegged with a ‘buy’ rating and a target price of 640p, a 28% premium to its close price on 30 September 2019.
With the shares trading at around 460p as of 1 October 2019, Next Fifteen carries a market cap of £426.7mln.